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To evaluate the incidence of fragility fractures associated with high-dose glucocorticoid therapy in patients with
systemic rheumatic disease.
Methods: A retrospective study of patients whowere treatedwith high-dose prednisolone (N0.8mg/kg) for sys-
temic rheumatic disease at Kobe University Hospital fromApril 1988 toMarch 2012. The primary outcomewas a
major osteoporotic fracture (deﬁned as a clinical vertebral, hip, forearm, or proximal humerus fracture) after
high-dose glucocorticoid therapy. For postmenopausal women and men over 40 of age, the patient's fracture
risk at the beginning of high-dose glucocorticoid therapy was assessed by theWorld Health Organization's Frac-
ture Risk Assessment Tool (FRAX®).
Results
Of 229 patients (median age: 49 years), 57 suffered a fragility fracture during the observation period (median ob-
servation period: 1558 days). Of 84 premenopausal patients, 5 suffered a fracture. In contrast, of 86 postmeno-
pausal female, 36 suffered a fracture. Fragility fractures were far more frequent than predicted by the FRAX®
score. Patients with FRAX® scores over 8.3% had a particularly high risk of fracture.
Conclusions
Fragility fractures associated with high-dose glucocorticoid therapy are common among postmenopausal
women. Extreme care should be taken especially for postmenopausal women when high-dose glucocorticoid
therapy is required.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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And systemic rheumatic disease1. Introduction
Glucocorticoid (GC) therapy is the primary treatment option for pa-
tientswith systemic rheumatic disease. Osteoporosis,which is a common
complication of high-dose GC therapy, is associatedwith signiﬁcantmor-
bidity and mortality. Although awareness of GC-induced osteoporosis
(GIO) has increased in recent years, GIO remains underdiagnosed and
undertreated. GIO's distinctive characteristics include rapid bone loss
and an increase in fracture risk shortly after beginningGC therapy; there-
fore, the primary preventionof fractures in high-risk individuals is critical
(Compston, 2010).ty for the Promotion of Science
Foundation grants.
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ma).
. This is an open access article underThe American College of Rheumatology (ACR) published Recommen-
dations for the Prevention andTreatment of Glucocorticoid-InducedOste-
oporosis in 1996 (American College of Rheumatology Task Force, 1996),
and various guidelines have since been published for other countries
(American College of Rheumatology Ad Hoc Committee, 2001) (Bone
and Tooth Society of Great Britain, National Osteoporosis Society, Royal
College of Physicians, Glucocorticoid-induced-osteoporosis guidelines
for prevention and treatment, 2002) (Devogelaer et al., 2006) (Watts et
al., 2008) (Grossman et al., 2010) (Suzuki et al., 2014). Some of these
guidelines use theWorld Health Organization's Fracture Risk Assessment
Tool (FRAX®),which uses a computer-based algorithm(http://www.shef.
ac.uk/FRAX) to calculate the 10-year probability of a major osteoporotic
fracture (deﬁnedas a clinical vertebral, hip, forearm, or proximal humerus
fracture) and the 10-year probability of a hip fracture (Watts et al., 2008)
(Grossman et al., 2010). FRAX® integrates seven clinical risk factors—a
prior fragility fracture, a parental history of hip fracture, smoking, use of
systemic corticosteroids, rheumatoid arthritis, secondary osteoporosis,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ute to fracture risk independently of bone mineral density (BMD)
(Kanis et al., 2008).
Although FRAX® is a valuable tool, it can underestimate risks be-
cause it does not include dose-response effects from contributing fac-
tors. For instance, there is strong evidence that the risks associated
with excessive alcohol consumption (Berg et al., 2008), smoking
(Hollenbach et al., 1993), and GC use (van Staa et al., 2000) are dose-re-
sponsive, and that the risk of fracture increases progressively with the
number of prior fractures (Lindsay et al., 2001). However, FRAX® scores
do not reﬂect these graded risks. Kanis et al. proposed adjusting FRAX®
scores according to GC dosage, using these simple rules: for low-dose
exposure, deﬁned as b2.5 mg/day prednisolone or the equivalent, the
probability of a major fracture is about 20% less than predicted by the
FRAX® score (although this result also depends on the patient's age).
For a dosage of 2.5–7.5 mg/day prednisolone, the unadjusted FRAX®
score can be used. For a dosage N7.5mg/day prednisolone, the probabil-
ity is revised upward by about 15% (Kanis et al., 2011). However, these
guidelines do not adequately assess the risks associated with high-dose
GC therapy (prednisolone 0.8 mg/kg/day or more, equal to 40mg pred-
nisolone/day for a 50-kg patient), which is often used for patients who
are severely affected by a rheumatic disease. The adjusted relative frac-
ture rate increases drastically for daily GC doses above 20mg predniso-
lone (van Staa et al., 2000). Despite this dramatic increase in the risk of
fractures, the incidence rate of fragility fractures after high-dose GC
therapy has not been reported.
Bisphosphonates, a family of anti-osteoporosis drugs that strongly
inhibit osteoclasts, are reported to treat GIO effectively (Saag et al.,
1998) (Cohen et al., 1999) (Reid et al., 2000) (Wallach et al., 2000)
(Adachi et al., 2001) (de Nijs et al., 2006) (Reid et al., 2009) (Stoch et
al., 2009) (Fahrleitner-Pammer et al., 2009) and are listed as a ﬁrst-line
pharmacologic intervention in several GIO-treatment guidelines (Bone
and Tooth Society of Great Britain, National Osteoporosis Society, Royal
College of Physicians, Glucocorticoid-induced-osteoporosis guidelines
for prevention and treatment, 2002) (Devogelaer et al., 2006) (Watts
et al., 2008) (Grossman et al., 2010) (Suzuki et al., 2014). Thus,many pa-
tients undergoing high-dose GC therapy also take bisphosphonates.
However, bisphosphonate therapy for GIO has been studied only in pa-
tients receiving 20 mg/day prednisolone or less, and its efﬁcacy for
preventing fragility fractures associated with high-dose GC therapy has
not been studied. Although newer, more effective GIO-prevention
drugs have become available recently or are in development, it is not
clear which patients on high-dose GC therapy should be given the
newer drugs.
This retrospective study was conducted to research the incidence
rate of fragility fractures in patients treated with high-dose GC therapy
in a real-world clinical setting, and to investigate the discrepancyTable 1
Baseline subject characteristics.
Disease Number Female Median Age
[25%–75%]
Median Observatio
Period [25%–75%]
SLE 76 66 (86.8) 30.5 [24–37] 2226 [1124–3085]
Vasculitisb 58 45 (75.9) 66 [47.8–70.8] 1166 [618.3–2087]
PM/DM 51 34 (66.7) 58 [47–69] 1655 [676–2587]
AOSD 12 7 (58.3) 37.5 [26–56] 1613 [1215–2335]
MCTD 7 6 (75) 42 [35–54] 1975 [1768–2540]
Othersc 25 12 (48) 63 [57.5–70] 833 [283–2650]
Total 229 170 (74.2) 49 [31–66] 1558 [803–2596]
AOSD= adult-onset Still's disease.
a FRAX is calculated for postmenopausal women and men over 40 of age.
b Vasculitis syndromes: Takayasu arteritis (11); giant-cell arteritis (11); microscopic polyan
angiitis (6); Behcet's disease (5); rheumatoid vasculitis (4); unclassiﬁed vasculitis (4). bOther d
osis (2); diffuse fasciitis (3); systemic sclerosis (2); relapsing polychondritis (2); idiopathic t
eosinophilic pneumonia (1); and pachymeningitis (1).
c 52 clinical spinal, 3 hip, 1 humerus and 1 wrist fracture.between the FRAX 10-year probability of a major osteoporotic fracture
and the actual fracture rate.
2. Methods
This study was reviewed and approved by the ethics board of Kobe
University Hospital prior to enrolling the subjects.
We retrospectively reviewedmedical records for all patients treated
for systemic rheumatic disease at Kobe University Hospital from April
1998 to March 2012. In total, 2094 medical records were reviewed.
The patients treated with prednisolone at a dose N0.8 mg/kg/day were
eligible for the study if they were followed continuously for at least
1 year after beginning treatment, andwere not treatedwith teriparatide
or denosumab. Based on these inclusion and exclusion criteria, 1865 re-
cords were discarded. We included 229 patients in the analysis.
The primary outcome for this study was a major osteoporotic frac-
ture (deﬁned as a clinical symptomatic vertebral, hip, forearm, or prox-
imal humerus fracture) after high-doseGC therapy.We identiﬁedmajor
osteoporotic fracture by retrospective medical record review. The diag-
nosis of osteoporotic fracture had been made mainly by rheumatolo-
gists or local orthopedist.
For postmenopausalwomen andmenover 40 years of age, we calcu-
lated the 10-year probability of a major osteoporotic fracture by using
Japanese version of FRAX®, with or without femoral BMD, at the start
of high-dose GC therapy. For patients who sustained a fragility fracture
during the observation period for any given course of GC therapy, we
used the data from the most recent admission and treatment period
prior to the fracture.
We collected clinical information of each patient. For postmeno-
pausal women and men over 40 years of age, we calculated the FRAX®
10-year probability of a major osteoporotic fracture, with or without
femoral BMD, at the start of high-dose GC therapy. Patients were con-
sidered to have received bisphosphonate and/or active vitamin D treat-
ment if they are prescribed those medicines for at least 80% of the
observation period. Patients who are prescribed bisphosphonate and/
or active vitamin D treatment for b80% of the observation period were
used as comparison subjects; most of these patients are prescribed
bisphosphonates or Vitamin D for b20% of the observation period.
To assess calibration (i.e., the degree of similarity between predicted
and observed risks), we stratiﬁed the postmenopausal women andmen
over 40 years of age into 4 groups according to their FRAX® score and
compared the 10-year probability of a major fragility fracture with the
observed incidence of fractures in our real-world clinical setting.
The fracture incidencewas calculated using the Kaplan-Meier meth-
od. We used the Cox proportional hazard model for multivariable anal-
ysis of the incidence of fragility fractures after high-doseGC therapy; the
variables analysed included the FRAX® 10-year probability of a majorn Median FRAXa
[25%–75%]
Bisphosphonates
prescription (%)
Prior high-dose
GC (%)
Fragility
Fracture (%)
5.3 [3.7–10.9] 28 (36.8) 30 (39.5) 6 (7.8)
14 [6.8–24] 38(65.5) 9 (15.5) 18 (31)
9 [5.9–14] 34 (66.7) 5 (9.8) 18 (35.3)
7.2 [3.2–9.8] 7 (58.3) 1 (8.3) 2 (16.7)
5.7 [2.8–10] 6 (85.7) 2 (29) 1 (14.2)
6.7 [4.9–13] 9 (36) 4 (16) 12 (48)
9 [5.2–15] 122 (53.2) 51 (22.2) 57c (24.9)
giitis (10); granulomatosis with polyangiitis (7); eosinophilic granulomatosis with poly-
iseases: IgG4-related disease (4); Castleman's disease (3); overlap syndrome (3); sarcoid-
hrombocytopenia (1); autoimmune haemolytic anaemia (1); autoimmune hepatitis (1);
Table 2
Characteristics of patients with and without fragility fractures.
Women (n=170) Men (n=59)
premenoposal (n=84) postmenoposal (n=86)
Fracture (n = 5) Fracture-free (n = 79) Fracture (n = 36) Fracture-free (n = 50) Fracture (n = 16) Fracture-free (n = 43)
Bisphosphonate prescription 1 (25%) 27 (34.2%) 24 (66.7%) 36 (72%) 8 (50%) 26 (60.5%)
Active Vitamin D prescription 3 (60%) 53 (67.1%) 17 (47.2%) 32 (64%) 9 (56.3%) 15 (34.9%)
Methylprednisolone pulse therapy 5 (100%) 43 (54.4%) 17 (47.2%) 16 (32%) 3 (18.8%) 21 (48.8%)
Prior high-dose GC treatment 4 (80%) 26 (32.9%) 5 (13.9%) 4 (8%) 6 (37.5%) 5 (11.6%)
FRAX (major fractures) − − 14.5 10 [4.9–16.8] 8.5 [5.0–12.0]1 6.1 [4.2–8.5]1
1 FRAX 10-year probability of a major osteoporotic fracture is calculated for male over 40 years of age.
Fig. 1. Kaplan-Meier analysis after high-dose glucocorticoid therapy.
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dose GC therapy, and the use of bisphosphonate, active vitamin D, or
methylprednisolone pulse therapies. We used estimated receiver oper-
ating characteristics (ROC) curves to estimate the optimal cut-off value
for the FRAX® 10-year probability of a major osteoporotic fracture, and
the sensitivity and speciﬁcity at the estimated optimal cut-off value. All
statistical analyses were performed using R version 3.0.3 (R Foundation
for Statistical Computing, Vienna, Austria), and P b 0.05 was considered
signiﬁcant. All statistical tests were two-tailed.
3. Results
This study included 229 patients. There were 76 patients with sys-
temic lupus erythematous (SLE), 58 with vasculitis syndrome, 51 with
polymyositis/dermatomyositis (PM/DM), 12with adult-onset Still's dis-
ease (AOSD), 7 with mixed connective tissue disease (MCTD) and 25
with other diseases. There were 84 premenopausal women, 86 post-
menopausal women and 59 men. The median observation period was
1558 days. Fragility fractures occurred in 57 patients during the obser-
vation period. Clinical spinal fractures occurred in 52 patients, hip frac-
tures in 3 patients, wrist in 1 patient and proximal humerus fracture in 1
patient. (Table 1).
When comparing patients with or without fractures during the ob-
servation period, we found no signiﬁcant difference in the percentage
of patients who received methylprednisolone pulse therapy or were
prescribedbisphosphonate or active VitaminD for at least 80%of the ob-
servation period (Table 2). Kaplan-Meier analysis showed postmeno-
pausal women are at greatly increased risk of fragility fractures after
high-dose GC therapy (Fig. 1).
To investigate the correlation between FRAX® and observed fracture
rate, we preformed subgroup analysis for the postmenopausal women
andmen over 40 years of age. The incidence of fragility fractures during
the observation period after high-dose GC therapy was considerably
higher than the incidence predicted by the FRAX® 10-year probability
scores assessed prior to the GC therapy (Table 3).
In multivariable analysis, bisphosphonate treatment, active vitamin
D treatment, and methylprednisolone pulse therapy were found not to
be related to fragility fractures. As expected, the FRAX® score was asso-
ciated with the incidence of fragility fractures. In addition, a history of
previous cycles of high-dose GC therapy was associated with a signiﬁ-
cant increase in the risk of fragility fractures (Table 4).
An ROC-curve analysis found that the optimal FRAX® 10-year prob-
ability cut-off for suffering major osteoporotic fractures after high-dose
GC therapy was 8.3% (sensitivity 70.6%, speciﬁcity 57.5%, AUC 0.661).
Kaplan-Meier analysis revealed a signiﬁcant difference in fracture fre-
quency between patients with FRAX® scores N8.3% and those with a
score of 8.3% or less (Fig. 2).
4. Discussion
The pathogenesis of GIO is thought to result from the direct effect of
excess GC on bone cells (osteoclasts, osteocytes, and osteoblasts) and
from indirect effects mediated by a negative calcium balance, thereduced production of gonadal hormones, and detrimental effects on
themuscle (Canalis et al., 2007) (Hofbauer & Rauner, 2009). GC's direct
effect is characterized by an early, transient phase of increased bone re-
sorption, along with reduced bone formation throughout the duration
of GC therapy. This early increase in bone resorption is thought to be a
major contributor to the bone loss and the increase in fracture risk
that develops within the ﬁrst few months of GC therapy (Compston,
2010).
In the ACR guidelines for GIO prevention, the FRAX 10-year risk of a
major osteoporotic fracture is deﬁned as low if b10%, medium if 10–
20%, and high if over 20%. However, the use of FRAX® to estimate GIO-
associated fracture risks has been criticized, since FRAX® does not take
GC dose-response effects into account and can thus underestimate frac-
ture risk (Suzuki et al., 2014) (Weinstein, 2011). FRAX® is deemed to be
appropriated for patients on a prednisolone treatment regimen of 2.5–
7.5 mg daily (Kanis et al., 2011). To our knowledge, FRAX® scores
have not been validated for patients on high-dose GC treatment regi-
mens. There are several likely reasons for this lapse. Relatively few pa-
tients require high-dose GC. The total GC dosage is not uniform among
patients or even for one patient over time, since the initial high GC dos-
age is gradually tapered off as the disease responds. High-dose GC ther-
apy is used to treat serious illnesses, and GIO generally receives less
attention than the original disease. Our data shows that fragility frac-
tures are occurred much higher frequently than FRAX® would predict.
Most importantly, the median observation period is much shorter
than 10 years that is the anticipated observation period for FRAX®
(Table 3).
Table 3
Discrepancy between the FRAX 10-year probability of a major osteoporotic fracture and observed fractures.
FRAX Mean FRAX (%) Number of patients Fractures Fracture rate (%) Median observation period (year)
Total (n = 131) 0%- b5.3% 3.6 33 6 18.2 1.4
5.3%- b9% 7 32 12 37.5 2
9%- b15% 11.7 30 13 43.3 2.1
≥15% 26.7 36 20 55.6 0.8
Postmenopausal women (n = 86) 0%- b6.3% 4.1 22 5 22.7 3.2
6.3%- b12% 8.7 19 8 42.1 3.9
12%- b22% 15.2 23 12 52.2 0.7
≥22% 32.9 22 11 50 0.7
Men over 40 years of age (n = 45) 0%- b4.5% 3.2 12 2 16.7 1.4
4.5%- b6.6% 5.5 10 3 30 0.3
6.6%- b9.2% 7.7 11 4 36.4 1.5
≥9.2% 12.3 12 6 50 1.6
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outcomes when treated with GCs and immunosuppressants. Since GIO
can cause fragility fractures even in young patients with rheumatic dis-
ease, attention should be given to preventing GIO.
Our data shows that the patients with SLE are lower risk of fragility
fractures than other rheumatic disease. This is attributed to the fact
that most of SLE patients are younger and greater population of pre-
menopausal women than other disease. In fact, it is reported that SLE it-
self is associated with low BMD or osteoporosis (Pineau et al., 2004)
(Tang et al., 2013) (Sun et al., 2015). There are some reasons such as in-
ﬂammation, vitaminD deﬁciency, and premature ovarian failure for risk
of low BMD (Lin & Grossman, 2016). Thosemechanisms are occurred in
other rheumatic diseases than SLE andmay also contribute to very high
frequency of fragility fracture in this study.
In this retrospective study, there is no signiﬁcant difference in frac-
ture incidence between bisphosphonates prescription group and com-
parison group. Currently, bisphosphonate is the most preferred drug
and has been proven the efﬁcacy for GIOP in many studies (Saag et al.,
1998) (Cohen et al., 1999) (Reid et al., 2000) (de Nijs et al., 2006) (Reid
et al., 2009) (Stoch et al., 2009) (Fahrleitner-Pammer et al., 2009). How-
ever, the primary end point of these studies are BMD, not fracture inci-
dence. In a post hoc analysis of the combined two studies and a follow
up study, bisphosphonate reduced the vertebral fracture rates compared
to the placebo group (Wallach et al., 2000) (Adachi et al., 2001). Al-
though a meta-analysis found that bisphosphonate reduced the odds of
spinal fracture by 24% in GIO patients [OR 0.76 (95% CI 0.37, 1.53)], this
result was not signiﬁcant (Homik et al., 2000).
There are all sorts of other reasons why bisphosphonate could not
reduce the fragility fracture risk in our data. First, since the osteoporotic
effect of GC is dose-dependent, it would not be surprising for the osteo-
porotic effect of high-dose GC therapy to overwhelm and effectively
cancel out the effect of bisphosphonates. Second, the timing of the initial
bisphosphonate treatment varied among the patients. Some started bis-
phosphonate treatment simultaneously with high-dose GC therapy,
while others began taking bisphosphonates one month after high-Table 4
Multivariate survival analysis.
Total (n = 131)
Adjusted hazard ratio 95% CI
FRAX (continuous, log-transformed) 2.26 1.52–3.38
Bisphosphonate comparison subjects 1 (reference)
Bisphosphonate prescription group 0.84 0.45–1.54
Active Vitamin D comparison subjects 1 (reference)
Active Vitamin D prescription group 0.82 0.47–1.43
No methylprednisolone pulse treatment 1 (reference)
Methylprednisolone pulse treatment group 1.14 0.61–2.13
No prior high-dose GC treatment 1 (reference)
Prior high-dose GC treatment 2.49 1.18–5.28
Adjusted by bisphosphonate, vitamin D, or mPSL pulse therapy, a history of high-dose GC, anddose GC treatment. The initial phase of GC therapy is a critical period
for preventing GIO. Third, we conjecture the other reason, the adher-
ence and persistence of bisphosphonates are usually poor. In observa-
tional studies, one year persistence rate of bisphosphonate is 27.9
to74.8% (Weycker et al., 2006) (Ideguchi et al., 2007) (Gallagher et al.,
2008) (Cotte et al., 2010) (Hadji et al., 2012). Recent study reported
that 80% of patients discontinued the bisphosphonates before complet-
ing 5 year treatment (LaFleur et al., 2015). The adherence to
bisphosphonates in our study is unclear and able to be examined accu-
rately. High-dose GC therapy is so high risk of the fragility fracture that
the potentially non-adherence medicine may be insufﬁcient. Another
possible explanation for ineffectiveness of bisphosphonates on high-
doseGC induced osteoporosis is based on reverse causality.We adjusted
osteoporotic risk factor by using FRAX® as moderator variables. Never-
theless, we cannot eliminate the bias or the reverse causality derived
from study design. Further work would be needed to assess the effects
of bisphosphonate for preventing fragility fracture in patients undergo-
ing high-dose GC therapy.
Our study found two risk factors for fragility fractures induced by
high-dose GCs: a high FRAX® 10-year probability for a major osteo-
porotic fracture, and two or more cycles of high-dose GC therapy.
Our ROC analysis found an optimal FRAX® cut-off of 8.3 for
predicting fragility fractures, even though the AUC of the ROC was
fairly low. Although the ACR's GIO guidelines deﬁne a FRAX® score
of 10% or less as low-risk, we found that postmenopausal patients
treated by high-dose GC therapy often suffered from fractures even
if their FRAX® score was below 10% and they were treated with bis-
phosphonate. Therefore, postmenopausal patients, especially with
a FRAX® score of 8.3% or more should be considered high-risk even
if they are taking bisphosphonate. Although the use of FRAX® to as-
sess GIO risk has been criticized (Compston, 2010) (Weinstein,
2011), our study shows the importance of FRAX® as a relative, not
absolute, risk-assessment tool for GIO, and supports the use of
FRAX® as a simple, comprehensive, and globally validated method
to assess fracture risk.Postmenopausal Women (n = 86) Men over 40 years of age (n = 45)
Adjusted hazard ratio 95% CI Adjusted hazard ratio 95% CI
2.41 1.45–3.99 3.21 1.03–9.98
1 (reference) 1 (reference)
0.67 0.31–1.44 1.21 0.41–3.54
1 (reference) 1 (reference)
0.72 0.36–1.44 1.27 0.40–3.87
1 (reference) 1 (reference)
1.68 0.79–3.61 0.4604 0.13–1.69
1 (reference) 1 (reference)
1.24 0.43–3.60 3.46 1.12–10.73
FRAX score.
Fig. 2. ROC curve analysis. The optimal cut-off of the FRAX® 10-year probability score associatedwith fragility fracture was 8.3%. Thus, the risk of fragility fractureswas signiﬁcantly higher
for patients with FRAX® scores of 8.3 or higher.
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spective, our results might be explained by reverse causation as men-
tioned above. Second, our studyhas lowpowerdue to a small sample size.
Our study is the ﬁrst to report the incidence of fractures with high-
dose GC therapy in a real-world clinical setting. We found a very high
incidence of fragility fractures in postmenopausal patients treated
with high-dose GC.
Because of some bias, our data did not show the fracture prevention
effect with bisphosphonate nor vitamin D in the patients underwent
high-dose GC therapy. New anti-osteoporotic drugs other than bisphos-
phonate are available or will soon launched. Teriparatide showed better
anti-osteoporotic effect than risedronate in GIO (Gluer et al., 2013)
(Amiche et al., 2016). The clinical trial with denosumab in GIO is in
progress, and the results are urgently needed. However, the studies
with newer drugs are not also conducted with high-dose GC therapy.
High-dose GC therapy is very high-risk for fragility fractures again. It is
important to prioritize clinical trials of the anti-osteoporotic drugs, so
that effective treatments can be used as soon as possible in the patients
who need high-dose GC therapy.
Disclosure of interest
Goichi Kageyama, Takaichi Okano, Yuzuru Yamamoto, Keisuke
Nishimura, Daisuke Sugiyama, Jun Saegusa, Goh Tsuji, Shunichi Kumagai,
and Akio Morinobu declare that they have no conﬂict of interest.
Author's contribution.
GK conceived of the study and involved in the overall study design
and data acquisition and analysis and drafted the manuscript. TO, YY
and KN contributed data acquisition. DS contributed data analysis. GT,
JS and SK provided critical input on data interpretation. AMparticipated
in its design, and helped draft themanuscript. All authors helped to crit-
ically revise the intellectual content of themanuscript and approved the
ﬁnal submission.
Acknowledgement
This study was supported by the Japan Society for the Promotion of
Science (JSPS) KAKENHI grants 25461475 and JapanOsteoporosis Foun-
dation grants.
Reference
Adachi, J.D., Saag, K.G., Delmas, P.D., Liberman, U.A., Emkey, R.D., Seeman, E., Lane, N.E.,
Kaufman, J.M., Poubelle, P.E., Hawkins, F., Correa-Rotter, R., Menkes, C.J., Rodriguez-Portales, J.A., Schnitzer, T.J., Block, J.A., Wing, J., McIlwain, H.H., Westhovens, R.,
Brown, J., Melo-Gomes, J.A., Gruber, B.L., Yanover, M.J., Leite, M.O., Siminoski, K.G.,
Nevitt, M.C., Sharp, J.T., Malice, M.P., Dumortier, T., Czachur, M., Carofano, W.,
Daifotis, A., 2001. Two-year effects of alendronate on bone mineral density and ver-
tebral fracture in patients receiving glucocorticoids: a randomized, double-blind, pla-
cebo-controlled extension trial. Arthritis Rheum. 44 (1), 202–211.
American College of Rheumatology Ad Hoc Committee (Ed.), 2001. Recommendations for
the prevention and treatment of glucocorticoid-induced osteoporosis: 2001
updateon Glucocorticoid-Induced Osteoporosis, Arthritis and rheumatism 44 (7),
1496–1503.
Recommendations for the prevention and treatment of glucocorticoid-induced osteopo-
rosis. American College of Rheumatology Task Force on Osteoporosis Guidelines, Ar-
thritis and Rheumatism 39(11) (1996) 1791–801.
Amiche, M.A., Albaum, J.M., Tadrous, M., Pechlivanoglou, P., Levesque, L.E., Adachi, J.D.,
Cadarette, S.M., 2016. Efﬁcacy of osteoporosis pharmacotherapies in preventing frac-
ture among oral glucocorticoid users: a network meta-analysis Osteoporosis interna-
tional. a journal established as result of cooperation between the European
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
27 (6), 1989–1998.
Berg, K.M., Kunins, H.V., Jackson, J.L., Nahvi, S., Chaudhry, A., Harris Jr., K.A., Malik, R.,
Arnsten, J.H., 2008. Association between alcohol consumption and both osteoporotic
fracture and bone density. Am. J. Med. 121 (5), 406–418.
Bone and Tooth Society of Great Britain, National Osteoporosis Society, Royal College of
Physicians, Glucocorticoid-induced-osteoporosis guidelines for prevention and
treatment.
Canalis, E., Mazziotti, G., Giustina, A., Bilezikian, J.P., 2007. Glucocorticoid-induced osteo-
porosis: pathophysiology and therapy, Osteoporosis international. a journal
established as result of cooperation between the European Foundation for Osteopo-
rosis and the National Osteoporosis Foundation of the USA 18 (10), 1319–1328.
Cohen, S., Levy, R.M., Keller, M., Boling, E., Emkey, R.D., Greenwald, M., Zizic, T.M.,Wallach, S.,
Sewell, K.L., Lukert, B.P., Axelrod, D.W., Chines, A.A., 1999. Risedronate therapy prevents
corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-
blind, placebo-controlled, parallel-group study. Arthritis Rheum. 42 (11), 2309–2318.
Compston, J., 2010. Management of glucocorticoid-induced osteoporosis. Nat. Rev.
Rheumatol. 6 (2), 82–88.
Cotte, F.E., Fardellone, P., Mercier, F., Gaudin, A.F., Roux, C., 2010. Adherence tomonthly and
weekly oral bisphosphonates in women with osteoporosis, Osteoporosis international.
a journal established as result of cooperation between the European Foundation for
Osteoporosis and the National Osteoporosis Foundation of the USA 21 (1), 145–155.
de Nijs, R.N., Jacobs, J.W., Lems, W.F., Laan, R.F., Algra, A., Huisman, A.M., Buskens, E., de
Laet, C.E., Oostveen, A.C., Geusens, P.P., Bruyn, G.A., Dijkmans, B.A., Bijlsma, J.W.,
Investigators, S., 2006. Alendronate or alfacalcidol in glucocorticoid-induced osteopo-
rosis. N. Engl. J. Med. 355 (7), 675–684.
Devogelaer, J.P., Goemaere, S., Boonen, S., Body, J.J., Kaufman, J.M., Reginster, J.Y.,
Rozenberg, S., Boutsen, Y., 2006. Evidence-based guidelines for the prevention and
treatment of glucocorticoid-induced osteoporosis: a consensus document of the Bel-
gian Bone Club, Osteoporosis international. A journal established as result of cooper-
ation between the European Foundation for Osteoporosis and the National
Osteoporosis Foundation of the USA 17 (1), 8–19.
Fahrleitner-Pammer, A., Piswanger-Soelkner, J.C., Pieber, T.R., Obermayer-Pietsch, B.M.,
Pilz, S., Dimai, H.P., Prenner, G., Tscheliessnigg, K.H., Hauge, E., Portugaller, R.H.,
Dobnig, H., 2009. Ibandronate prevents bone loss and reduces vertebral fracture
risk in male cardiac transplant patients: a randomized double-blind, placebo-con-
trolled trial. J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res. 24 (7), 1335–1344.
Gallagher, A.M., Rietbrock, S., Olson, M., van Staa, T.P., 2008. Fracture outcomes related to
persistence and compliance with oral bisphosphonates. J. Bone Miner. Res. Off. J. Am.
Soc. Bone Miner. Res. 23 (10), 1569–1575.
8 G. Kageyama et al. / Bone Reports 6 (2017) 3–8C.C. Gluer, F. Marin, J.D. Ringe, F. Hawkins, R. Moricke, N. Papaioannu, P. Farahmand, S.
Minisola, G. Martinez, J.M. Nolla, C. Niedhart, N. Guanabens, R. Nuti, E. Martin-Mola,
F. Thomasius, G. Kapetanos, J. Pena, C. Graeff, H. Petto, B. Sanz, A. Reisinger, P.K.
Zysset, Comparative effects of teriparatide and risedronate in glucocorticoid-induced
osteoporosis in men: 18-month results of the EuroGIOPs trial, J. Bone Miner. Res. Off.
J. Am. Soc. Bone Miner. Res. 28(6) (2013) 1355–68.
Grossman, J.M., Gordon, R., Ranganath, V.K., Deal, C., Caplan, L., Chen, W., Curtis, J.R., Furst,
D.E., McMahon, M., Patkar, N.M., Volkmann, E., Saag, K.G., 2010. American College of
Rheumatology 2010 recommendations for the prevention and treatment of glucocor-
ticoid-induced osteoporosis. Arthritis care & research 62 (11), 1515–1526.
Hadji, P., Claus, V., Ziller, V., Intorcia, M., Kostev, K., Steinle, T., 2012. GRAND: The German
retrospective cohort analysis on compliance and persistence and the associated risk
of fractures in osteoporotic women treated with oral bisphosphonates. Osteoporosis
international: a journal established as result of cooperation between the European
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
23 (1), 223–231.
Hofbauer, L.C., Rauner, M., 2009. Minireview: live and let die: molecular effects of gluco-
corticoids on bone cells. Mol. Endocrinol. 23 (10), 1525–1531.
Hollenbach, K.A., Barrett-Connor, E., Edelstein, S.L., Holbrook, T., 1993. Cigarette smoking
and bone mineral density in older men and women. Am. J. Public Health 83 (9),
1265–1270.
Homik, J., Cranney, A., Shea, B., Tugwell, P., Wells, G., Adachi, R., Suarez-Almazor, M., 2000.
Bisphosphonates for steroid induced osteoporosis. Cochrane Database Syst. Rev. (2),
CD001347.
Ideguchi, H., Ohno, S., Hattori, H., Ishigatsubo, Y., 2007. Persistence with bisphosphonate
therapy including treatment courses with multiple sequential bisphosphonates in
the real world. Osteoporosis international: a journal established as result of coopera-
tion between the European Foundation for Osteoporosis and the National Osteoporo-
sis Foundation of the USA 18 (10), 1421–1427.
Kanis, J.A., Johnell, O., Oden, A., Johansson, H., McCloskey, E., 2008. FRAX and the assess-
ment of fracture probability in men and women from the UK, Osteoporosis interna-
tional. a journal established as result of cooperation between the European
Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
19 (4), 385–397.
Kanis, J.A., Hans, D., Cooper, C., Baim, S., Bilezikian, J.P., Binkley, N., Cauley, J.A., Compston,
J.E., Dawson-Hughes, B., El-Hajj Fuleihan, G., Johansson, H., Leslie, W.D., Lewiecki,
E.M., Luckey, M., Oden, A., Papapoulos, S.E., Poiana, C., Rizzoli, R., Wahl, D.A.,
McCloskey, E.V., 2011. F.I. Task Force of the, Interpretation and use of FRAX in clinical
practice, Osteoporosis international. a journal established as result of cooperation be-
tween the European Foundation for Osteoporosis and the National Osteoporosis
Foundation of the USA 22 (9), 2395–2411.
LaFleur, J., DuVall, S.L., Willson, T., Ginter, T., Patterson, O., Cheng, Y., Knippenberg, K.,
Haroldsen, C., Adler, R.A., Curtis, J.R., Agodoa, I., Nelson, R.E., 2015. Analysis of osteo-
porosis treatment patterns with bisphosphonates and outcomes among postmeno-
pausal veterans. Bone 78, 174–185.
Lin, T., Grossman, J., 2016. Prevention and treatment of bone disease in systemic lupus er-
ythematosus. Current Treatment Options in Rheumatology 2 (1), 21–35.
Lindsay, R., Silverman, S.L., Cooper, C., Hanley, D.A., Barton, I., Broy, S.B., Licata, A.,
Benhamou, L., Geusens, P., Flowers, K., Stracke, H., Seeman, E., 2001. Risk of new ver-
tebral fracture in the year following a fracture. JAMA 285 (3), 320–323.Pineau, C.A., Urowitz, M.B., Fortin, P.J., Ibanez, D., Gladman, D.D., 2004. Osteoporosis in
systemic lupus erythematosus: factors associated with referral for bone mineral den-
sity studies, prevalence of osteoporosis and factors associated with reduced bone
density. Lupus 13 (6), 436–441.
Reid, D.M., Hughes, R.A., Laan, R.F., Sacco-Gibson, N.A., Wenderoth, D.H., Adami, S.,
Eusebio, R.A., Devogelaer, J.P., 2000. Efﬁcacy and safety of daily risedronate in the
treatment of corticosteroid-induced osteoporosis in men and women: a randomized
trial. European Corticosteroid-Induced Osteoporosis Treatment Study. J. Bone Miner.
Res. Off. J. Am. Soc. Bone Miner. Res. 15 (6), 1006–1013.
Reid, D.M., Devogelaer, J.P., Saag, K., Roux, C., Lau, C.S., Reginster, J.Y., Papanastasiou, P.,
Ferreira, A., Hartl, F., Fashola, T., Mesenbrink, P., Sambrook, P.N., 2009. H. investiga-
tors, Zoledronic acid and risedronate in the prevention and treatment of glucocorti-
coid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-
dummy, randomised controlled trial. Lancet 373 (9671), 1253–1263.
Saag, K.G., Emkey, R., Schnitzer, T.J., Brown, J.P., Hawkins, F., Goemaere, S., Thamsborg, G.,
Liberman, U.A., Delmas, P.D., Malice, M.P., Czachur, M., Daifotis, A.G., 1998.
Alendronate for the prevention and treatment of glucocorticoid-induced osteoporo-
sis. Glucocorticoid-InducedOsteoporosis Intervention Study Group, The NewEngland
journal of medicine 339 (5), 292–299.
Stoch, S.A., Saag, K.G., Greenwald, M., Sebba, A.I., Cohen, S., Verbruggen, N., Giezek, H.,
West, J., Schnitzer, T.J., 2009. Once-weekly oral alendronate 70 mg in patients with
glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clin-
ical trial. J. Rheumatol. 36 (8), 1705–1714.
Sun, Y.N., Feng, X.Y., He, L., Zeng, L.X., Hao, Z.M., Lv, X.H., Pu, D., 2015. Prevalence and pos-
sible risk factors of low bone mineral density in untreated female patients with sys-
temic lupus erythematosus. Biomed. Res. Int. 2015, 510514.
Suzuki, Y., Nawata, H., Soen, S., Fujiwara, S., Nakayama, H., Tanaka, I., Ozono, K., Sagawa, A.,
Takayanagi, R., Tanaka, H., Miki, T., Masunari, N., Tanaka, Y., 2014. Guidelines on theman-
agement and treatment of glucocorticoid-induced osteoporosis of the Japanese Society
for Bone and Mineral Research: 2014 update. J. Bone Miner. Metab. 32 (4), 337–350.
Tang, X.L., Grifﬁth, J.F., Qin, L., Hung, V.W., Kwok, A.W., Zhu, T.Y., Kun, E.W., Leung, P.C., Li,
E.K., Tam, L.S., 2013. SLE disease per se contributes to deterioration in bone mineral
density, microstructure and bone strength. Lupus 22 (11), 1162–1168.
van Staa, T.P., Leufkens, H.G., Abenhaim, L., Zhang, B., Cooper, C., 2000. Oral corticosteroids
and fracture risk: relationship to daily and cumulative doses. Rheumatology 39 (12),
1383–1389.
Wallach, S., Cohen, S., Reid, D.M., Hughes, R.A., Hosking, D.J., Laan, R.F., Doherty, S.M.,
Maricic, M., Rosen, C., Brown, J., Barton, I., Chines, A.A., 2000. Effects of risedronate
treatment on bone density and vertebral fracture in patients on corticosteroid thera-
py. Calcif. Tissue Int. 67 (4), 277–285.
Watts, N.B., Lewiecki, E.M., Miller, P.D., Baim, S., 2008. National Osteoporosis Foundation
2008 Clinician's guide to prevention and treatment of osteoporosis and the World
Health Organization fracture risk assessment tool (FRAX): what they mean to the
bone densitometrist and bone technologist. J. Clin. Densitom. 11 (4), 473–477.
Weinstein, R.S., 2011. Clinical practice. Glucocorticoid-induced bone disease. N. Engl.
J. Med. 365 (1), 62–70.
Weycker, D., Macarios, D., Edelsberg, J., Oster, G., 2006. Compliance with drug therapy for
postmenopausal osteoporosis, Osteoporosis international. a journal established as re-
sult of cooperation between the European Foundation for Osteoporosis and the Na-
tional Osteoporosis Foundation of the USA 17 (11), 1645–1652.
